RxDoctor Payments DataLook up a doctor →

Prakash Balan, MD

Interventional Cardiology · Chandler, AZNPI 1285830661

Payments from drug & device makers

$321,070in general payments, 2019–2025

Across 506 payments — averaging $634.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Edwards Lifesciences$180K
  • Chiesi USA, Inc.$36K
  • Abbott$35K
  • Abiomed$24K
  • Boston Scientific$18K
  • Osprey Medical Inc$7K
  • plus $20K from 39 others

What the payments were for

  • Consulting fees$7,9079%
  • Speaking & faculty fees$45,73854%
  • Travel & lodging$16,49419%
  • Food & beverage$14,84317%
  • Education$80%
  • Other$930%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$321,070 in reported general payments places this provider in the 90th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$573,268
Medicare patients
1,587
Services billed
6,227

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban109$166,159
XareltoRivaroxaban34$50,892
EntrestoSacubitril/Valsartan33$41,769
JardianceEmpagliflozin25$37,973
Repatha SureclickEvolocumab20$22,257
Metoprolol Succinate274$3,715
Rosuvastatin Calcium154$2,269
Losartan Potassium185$2,082
Atorvastatin Calcium200$1,810
Nifedipine ErNifedipine24$1,193
Ezetimibe42$1,169
Carvedilol80$833
Lisinopril103$817
Flecainide Acetate12$787
Amlodipine Besylate182$749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$248$166,159109 claims
Johnson & JohnsonXarelto$14$50,89234 claims
NovartisEntresto$445$41,76933 claims
Boehringer IngelheimJardiance$115$37,97325 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Chandler

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →